Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01786603|
Recruitment Status : Completed
First Posted : February 8, 2013
Results First Posted : January 27, 2020
Last Update Posted : January 27, 2020
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function. Motor neurons are responsible for sending signals to muscles in our bodies to trigger movement. While there are drugs to help relieve symptoms of ALS, there is no cure for ALS.
Rasagiline is a drug with possible neuroprotective characteristics. Neuroprotective means that the nervous system may be protected against weakening. It is known that rasagiline has possible neuroprotective characteristics, but the effectiveness of rasagiline for patients with ALS has not been tested. Rasagiline is approved for the treatment of Parkinson's disease.
Rasagiline for treatment of ALS is not approved by the U.S. Food and Drug Administration (FDA) and is investigational. Investigational drugs are studied to find out if they are safe and effective in the treatment of diseases or conditions.
By doing this study, researchers hope to learn if rasagiline is safe and slows disease progression in patients with ALS.
Funding Source - FDA OOPD (FDA Orphan Products Division).
|Condition or disease||Intervention/treatment||Phase|
|Amyotrophic Lateral Sclerosis (ALS)||Drug: Rasagiline Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis|
|Actual Study Start Date :||November 21, 2013|
|Actual Primary Completion Date :||July 27, 2016|
|Actual Study Completion Date :||July 27, 2016|
Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
Rasagiline 2mg once a day for 12 months.
Other Name: Azilect
Placebo Comparator: Placebo
Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
- ALS Functional Rating Scale-Revised (ALSFRS-R) [ Time Frame: ALS Functional Rating Scale-Revised (ALSFRS-R) Difference from Baseline to Month 12 ]Difference in ALS Functional Rating Scale - Revised (ALSFRS-R) score. The ALSFRS-R is an ordinal rating scale that assesses 12 functional activities. Each activity is scored between 0-4, with a total score ranging from 48 (normal function) to 0 (no function).
- Change in Vital Capacity (VC) [ Time Frame: Vital Capacity Change from Baseline to Month 12 ]Determine if decline in vital capacity is slower in participants taking 2 mg rasagiline than controls.
- Change in Quality of Life [ Time Frame: Quality of Life Change from Baseline to Month 12 ]Participants completed the single-item ALSQOL (ALS Quality of Life) which asks participants to rank their global quality of life, considering all parts of their lives - physical, emotional, social, spiritual and financial - in the last 7 days and rate on a scale of 0 (very bad) to 10 (excellent).
- Number of Participants With Adverse Events [ Time Frame: Adverse Events from Baseline to Month 12 ]Determine if participants on rasagiline 2 mg had a different safety profile than patients not on rasagiline. Adverse event information to be collected from date of enrollment until end of study participation.
- Difference in Survival Status Between Study Groups [ Time Frame: Survival status at Month 12 ]Determine if there is a difference in survival between participants on rasagiline than patients not on rasagiline
- Effect of Study Drug on Apoptosis Markers [ Time Frame: Apoptosis Marker change from Baseline to Month 12 ]Effect of rasagiline on the apoptosis markers (Annexin V stain) in participants with ALS. Assessed at baseline, month 6, and month 12; change from baseline to month 12 reported. Extra time point was not a pre-specified Primary or Secondary Outcome Measure.
- Effect of Study Drug on Oxidative Stress [ Time Frame: Oxidative Stress change from Baseline to Month 12 ]Determine if oxygen radical antioxidant capacity is targeted by rasagiline in participants with ALS. Assessed at baseline, month 6, and month 12; change from baseline to month 12 reported. Extra time point was not a pre-specified Primary or Secondary Outcome Measure.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||21 Years to 80 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- A clinical diagnosis of laboratory-supported probable, probable, or definite ALS, according to a modified El Escorial criteria, by the study investigator (Appendix IV).
- 21 to 80 years of age inclusive.
- VC greater or equal to 75% of predicted at screening and baseline.
- Onset of weakness within 2 years prior to enrollment.
- If patients are taking riluzole for ALS, they must be on a stable dose for at least thirty days prior to the baseline visit.
- Women of childbearing age must be non-lactating and surgically sterile or using an effective method of birth control and have a negative pregnancy test.
- Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB).
- Requirement for tracheotomy ventilation or non-invasive ventilation for > 23 hours per day.
- Patients on sympathomimetic agents. This includes pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine.
- Patients on analgesics with serotoninergic properties such as meperidine, tramadol, methadone and propoxyphene, flexeril.
- Patients on fluoxetine or fluvoxamine.
- Patients taking amitriptyline > 50 mg/d, trazodone and sertraline > 100 mg/d, citalopram > 20 mg/d or paroxetine > 30 mg/d.
- Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease, etc).
- Clinically significant history of unstable medical illness (unstable angina, advanced cancer, etc) over the last 30 days.
- Has a diaphragm pacing device or plan on obtaining a diaphragm pacing device during the course of the study.
- History of renal disease.
- History of liver disease.
- Current pregnancy or lactation.
- Limited mental capacity such that the patient cannot provide written informed consent or comply with evaluation procedures.
- History of recent alcohol or drug abuse or noncompliance with treatment or other experimental protocols.
- Vital Capacity (VC) < 75% of predicted.
- Receipt of any investigational drug within the past 30 days.
- Women with the potential to become pregnant who are not practicing effective birth control.
- Poorly controlled hypertensive subjects or resting systolic blood pressure (SBP) > 160 mmHg and/or diastolic (DBP) > 95 mmHg.
- Use of BiPAP at screening.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01786603
|United States, Arizona|
|Phoenix Neurological Associates|
|Phoenix, Arizona, United States, 85018|
|United States, California|
|University of California - Irvine|
|Irvine, California, United States, 92868|
|California Pacific Medical Center|
|San Francisco, California, United States, 94115|
|United States, Kansas|
|University of Kansas Medical Center|
|Kansas City, Kansas, United States, 66160|
|United States, Missouri|
|St. Louis University|
|Saint Louis, Missouri, United States, 63104|
|United States, Nebraska|
|University of Nebraska|
|Omaha, Nebraska, United States, 68198|
|United States, New York|
|New York, New York, United States, 10032|
|United States, Oregon|
|Oregon Health and Science University|
|Portland, Oregon, United States, 97239|
|United States, Pennsylvania|
|University of Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19107|
|United States, Texas|
|UT Southwestern Medical Center|
|Dallas, Texas, United States, 75390|
|Principal Investigator:||Richard Barohn, MD||University of Kansas Medical Center|
|Responsible Party:||Richard Barohn, MD, Gertrude and Dewey Zeigler Professor of Neurology and Chair, University of Kansas Medical Center|
|Other Study ID Numbers:||
R01FD003739 ( U.S. FDA Grant/Contract )
|First Posted:||February 8, 2013 Key Record Dates|
|Results First Posted:||January 27, 2020|
|Last Update Posted:||January 27, 2020|
|Last Verified:||January 2020|
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Nervous System Diseases
Spinal Cord Diseases
Central Nervous System Diseases
Monoamine Oxidase Inhibitors
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs